Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rybrevant Faspro
- Development stage
- Approved
- Lead developer
- Janssen Biotech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Rybrevant Faspro is a subcutaneous combination of amivantamab, a bispecific monoclonal antibody, and hyaluronidase-lpuj, an endoglycosidase. Developed by Janssen Biotech (a Johnson & Johnson company), the drug is designed to target both the epidermal growth factor receptor (EGFR) and the MET receptor. It is indicated for the treatment of adult patients with metastatic or inoperable non-small cell lung cancer (NSCLC) who harbor specific EGFR mutations, including exon 19 deletions or exon 21 L858R substitutions. The inclusion of hyaluronidase allows for subcutaneous administration, which significantly reduces the time required for delivery compared to intravenous infusion and lowers the incidence of administration-related reactions. It can be administered as a monotherapy or in combination with other agents such as lazertinib or platinum-based chemotherapy.
- Brand names
- Rybrevant Faspro
- Other names
- amivantamab and hyaluronidase-lpujamivantamab-hyaluronidase
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on Rybrevant Faspro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rybrevant Faspro.